Page 7 - reflections_dyslipidaemia_newsletter9_Final
P. 7
REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #9 2025
CLICK HERE Dyslipidaemia
TO LISTEN TO JAMA ASSOCIATE EDITOR
PRADEEP NATARAJAN TALK TO AUTHOR
THOMAS H. MARWICK TO DISCUSS
A STUDY LOOKING AT WHETHER A
CAC SCORE-INFORMED STRATEGY
COULD SLOW THE PROGRESSION OF
CORONARY PLAQUE VOLUME (10:22).
CLICK HERE
FOR THE LINK TO FULL ARTICLE
TREATMENT
Early ezetimibe initiation after myocardial infarction protects against later
cardiovascular outcomes in the SWEDEHEART registry.
Leosdottir M, et al. J Am Coll Cardiol. 2025;85(15):1550-1564.
At least two-thirds of patients with a myocardial infarction (MI) to be problematic as about 75% to 80% of MI patients failed to
are statin-naïve at the time of presentation so lipid-lowering achieve their LDL-C goals with statin monotherapy, showing that
therapy (LLT) is initiated for the first time after an MI. Current this stepwise approach inherently leads to delays in achieving
global guidelines for patients post-MI recommend high- recommended LDL-C goals. Given that the impact of early
intensity statins as close to the MI as possible, with escalation versus late initiation of statin-ezetimibe combination therapy on
of treatment after subsequent LDL-C measurements, with patient outcomes was unknown, this study looked to assess the
addition of ezetimibe or PCSK9 inhibitors. This strategy proved consequences of such delayed treatment escalation.
Graphical abstract
LDL-C, low-density lipoprotein
cholesterol; LLT, lipid-lowering
therapy; MACE, major adverse
cardiovascular events; MI,
myocardial infarction; Ref,
reference.
TABLE OF CONTENTS
